ID

41169

Description

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT01933932

Link

https://clinicaltrials.gov/show/NCT01933932

Keywords

Versions (1)
  1. 7/4/20 7/4/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 4, 2020

DOI

To request one please log in.

License

Creative Commons BY-NC 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01933932

English

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01933932

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
provision of signed, written and dated informed consent prior to any study specific procedures
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
male or female, aged 18 years or older
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
histological or cytological confirmation of locally advanced or metastatic nsclc (iiib-iv)
Description

Locally Advanced Lung Non-Small Cell Carcinoma TNM clinical staging | Metastatic non-small cell lung cancer TNM clinical staging

Data type

boolean

Alias
UMLS CUI [1,1]
C5205550
UMLS CUI [1,2]
C3258246
UMLS CUI [2,1]
C0278987
UMLS CUI [2,2]
C3258246
kras mutation positive tumour sample as determined by the designated testing laboratory
Description

Tumor tissue sample KRAS Gene Mutation Positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C1517649
UMLS CUI [1,3]
C1514241
failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
Description

Cancer treatment First line Failed | Advanced disease | Recurrent disease

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C1708063
UMLS CUI [1,3]
C0231175
UMLS CUI [2]
C0679246
UMLS CUI [3]
C0277556
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
mixed small cell and non-small cell lung cancer histology.
Description

Small cell carcinoma of lung Non-Small Cell Lung Carcinoma Mixed

Data type

boolean

Alias
UMLS CUI [1,1]
C0149925
UMLS CUI [1,2]
C0007131
UMLS CUI [1,3]
C0205430
received >1 prior anti-cancer drug regimen for advanced or metastatic nsclc. patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
Description

Cancer treatment Quantity Advanced Lung Non-Small Cell Carcinoma | Cancer treatment Quantity Metastatic non-small cell lung cancer | Disease Progression During Maintenance therapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C5206378
UMLS CUI [2,1]
C0920425
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0278987
UMLS CUI [3,1]
C0242656
UMLS CUI [3,2]
C0347984
UMLS CUI [3,3]
C0677908
receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment
Description

Cancer treatment Systemic

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
other concomitant anti-cancer therapy agents excepts steroids
Description

Antineoplastic Agents Except Steroids

Data type

boolean

Alias
UMLS CUI [1,1]
C0003392
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C0038317
prior treatment with a mitogen-activated protein kinase (mek) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable).
Description

Prior Therapy | Mitogen-Activated Protein Kinase Inhibitor | docetaxel

Data type

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C1513344
UMLS CUI [3]
C0246415
last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment
Description

Therapeutic radiology procedure Recent | Palliative course of radiotherapy Recent

Data type

boolean

Alias
UMLS CUI [1,1]
C1522449
UMLS CUI [1,2]
C0332185
UMLS CUI [2,1]
C0475092
UMLS CUI [2,2]
C0332185
Back to the top of the page

Similar models

Eligibility Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV NCT01933932

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
provision of signed, written and dated informed consent prior to any study specific procedures
boolean
C0021430 (UMLS CUI [1])
Age
Item
male or female, aged 18 years or older
boolean
C0001779 (UMLS CUI [1])
Locally Advanced Lung Non-Small Cell Carcinoma TNM clinical staging | Metastatic non-small cell lung cancer TNM clinical staging
Item
histological or cytological confirmation of locally advanced or metastatic nsclc (iiib-iv)
boolean
C5205550 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0278987 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
Tumor tissue sample KRAS Gene Mutation Positive
Item
kras mutation positive tumour sample as determined by the designated testing laboratory
boolean
C0475358 (UMLS CUI [1,1])
C1517649 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
Cancer treatment First line Failed | Advanced disease | Recurrent disease
Item
failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
boolean
C0920425 (UMLS CUI [1,1])
C1708063 (UMLS CUI [1,2])
C0231175 (UMLS CUI [1,3])
C0679246 (UMLS CUI [2])
C0277556 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Small cell carcinoma of lung Non-Small Cell Lung Carcinoma Mixed
Item
mixed small cell and non-small cell lung cancer histology.
boolean
C0149925 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205430 (UMLS CUI [1,3])
Cancer treatment Quantity Advanced Lung Non-Small Cell Carcinoma | Cancer treatment Quantity Metastatic non-small cell lung cancer | Disease Progression During Maintenance therapy
Item
received >1 prior anti-cancer drug regimen for advanced or metastatic nsclc. patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
boolean
C0920425 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C5206378 (UMLS CUI [1,3])
C0920425 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0278987 (UMLS CUI [2,3])
C0242656 (UMLS CUI [3,1])
C0347984 (UMLS CUI [3,2])
C0677908 (UMLS CUI [3,3])
Cancer treatment Systemic
Item
receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Antineoplastic Agents Except Steroids
Item
other concomitant anti-cancer therapy agents excepts steroids
boolean
C0003392 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
Prior Therapy | Mitogen-Activated Protein Kinase Inhibitor | docetaxel
Item
prior treatment with a mitogen-activated protein kinase (mek) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable).
boolean
C1514463 (UMLS CUI [1])
C1513344 (UMLS CUI [2])
C0246415 (UMLS CUI [3])
Therapeutic radiology procedure Recent | Palliative course of radiotherapy Recent
Item
last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment
boolean
C1522449 (UMLS CUI [1,1])
C0332185 (UMLS CUI [1,2])
C0475092 (UMLS CUI [2,1])
C0332185 (UMLS CUI [2,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial